Eupraxia Pharmaceuticals (EPRX) said late Monday it has filed a preliminary prospectus supplement to its short form base shelf prospectus for a public offering of shares.

The firm expects to grant its underwriters a 30-day option to buy up to an additional 15% of shares offered in the offering.

Shares were over 2% lower in after-market activity.